These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37878693)

  • 21. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
    Zimmermann M; Murina O; Reijns MAM; Agathanggelou A; Challis R; Tarnauskaitė Ž; Muir M; Fluteau A; Aregger M; McEwan A; Yuan W; Clarke M; Lambros MB; Paneesha S; Moss P; Chandrashekhar M; Angers S; Moffat J; Brunton VG; Hart T; de Bono J; Stankovic T; Jackson AP; Durocher D
    Nature; 2018 Jul; 559(7713):285-289. PubMed ID: 29973717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.
    Zhan Z; Zhang J; Liang H; Wang C; Hong L; Liu W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2400140. PubMed ID: 38973255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
    Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
    Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.
    Krastev DB; Li S; Sun Y; Wicks AJ; Hoslett G; Weekes D; Badder LM; Knight EG; Marlow R; Pardo MC; Yu L; Talele TT; Bartek J; Choudhary JS; Pommier Y; Pettitt SJ; Tutt ANJ; Ramadan K; Lord CJ
    Nat Cell Biol; 2022 Jan; 24(1):62-73. PubMed ID: 35013556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
    Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
    Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
    Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
    Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
    Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone ADP-ribosylation promotes resistance to PARP inhibitors by facilitating PARP1 release from DNA lesions.
    Zentout S; Imburchia V; Chapuis C; Duma L; Schützenhofer K; Prokhorova E; Ahel I; Smith R; Huet S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322689121. PubMed ID: 38865276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of PARP as a successful target for cancer therapy.
    Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
    Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
    Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.
    Lin X; Jiang W; Rudolph J; Lee BJ; Luger K; Zha S
    Nucleic Acids Res; 2022 Apr; 50(7):3958-3973. PubMed ID: 35349716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
    Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
    J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP trapping is governed by the PARP inhibitor dissociation rate constant.
    Gopal AA; Fernandez B; Delano J; Weissleder R; Dubach JM
    Cell Chem Biol; 2024 Jul; 31(7):1373-1382.e10. PubMed ID: 38262416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.